Findings

What do systematic reviews say?

475 questions · 487 findings · 49 reviews · Breast Cancer

Sort:Best matchNewestHighest certainty Download CSV

No studies found 44 · 9%GRADE not reported 14 · 2.9%Very low 108 · 22.2%Low 128 · 26.3%Moderate 107 · 22%High 86 · 17.7%

Intervention not reported

Disease‐free survival ‐ not reported · overweight and obese breast cancer survivors

The review found no eligible studies for this question.

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events · overweight and obese breast cancer survivors

The review found no eligible studies for this question.

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Change in quality of life ‐ overall scales · overweight and obese breast cancer survivors

The review found no eligible studies for this question.

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Breast cancer recurrence · overweight and obese breast cancer survivors

The intervention showed no clear difference in breast cancer recurrence (low certainty).

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
RR 1.95 [0.68, 5.6]
4 studies · 281 participants
Low

Intervention not reported

Change in body weight · overweight and obese breast cancer survivors

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
21 studies · 1751 participants
Low

Intervention not reported

Change in BMI · overweight and obese breast cancer survivors

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 1353 participants
Low

Intervention not reported

Change in waist circumference · overweight and obese breast cancer survivors

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 1193 participants
Low

Intervention not reported

Disease‐free survival · overweight and obese breast cancer survivors

The review found no eligible studies for this question.

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events · overweight and obese breast cancer survivors

The intervention showed no clear difference in adverse events (high certainty).

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
RR 0.94 [0.76, 1.17]
4 studies · 394 participants
High

Intervention not reported

Change in quality of life ‐ overall scales · overweight and obese breast cancer survivors

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 867 participants
Low

Intervention not reported

Overall survival · overweight and obese breast cancer survivors

The review found no eligible studies for this question.

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Exercise vs usual care

Overall change in worst pain scores · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 284 participants
Very low

Exercise vs usual care

Stiffness · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Low

Exercise vs usual care

Change in grip strength · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Very low

Exercise vs usual care

Overall change in health‐related quality of life · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Very low

Exercise vs usual care

Cancer‐specific quality of life · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 136 participants
Very low

Exercise vs usual care

Adverse effects secondary to the intervention · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 331 participants
Low

Exercise vs usual care

Adherence to aromatase inhibitors · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

It is very uncertain whether exercise therapies changes adherence to aromatase inhibitors compared with standard care (very low certainty).

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
OR 2.43 [0.41, 14.63]
2 studies · 224 participants
Very low

Indocyanine Green Angiography (ICGA) vs clinical evaluation

Mastectomy skin flap necrosis (number of women with mastectomy skin flap necrosis within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy

It is very uncertain whether indocyanine Green Angiography (ICGA) changes mastectomy skin flap necrosis (number of women with mastectomy skin… compared with clinical evaluation (very low certainty).

1 finding from 1 review

Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… 2020 · Cochrane Headline outcomes only
RR 0.79 [0.4, 1.56]
3 studies · 573 participants
Very low

Indocyanine Green Angiography (ICGA) vs clinical evaluation

Infection (number of breasts with infection within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy

It is very uncertain whether indocyanine Green Angiography (ICGA) changes infection (number of breasts with infection within 30 days after… compared with clinical evaluation (very low certainty).

1 finding from 1 review

Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… 2020 · Cochrane Headline outcomes only
RR 0.65 [0.44, 0.97]
Studies not reported
Very low